Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Radiation with or without Tremelimumab in Bladder Cancer
NCT03150836Phase 2Withdrawn
- Start
- Oct 2017
- Primary completion
- Sep 2021
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in bladder cancer. Planned start Oct 2017; status: withdrawn.
02
Drugs
durvalumabtremelimumab
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT03150836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03150836.